Machine learning screening reveals ABBV-744 as a modulator of P2Y purinergic receptors
Researchers used consensus machine-learning classifiers trained on known P2Y6 agonists to select compounds for pharmacological testing. The anticancer drug ABBV-744 showed non-surmountable inhibition of UDP-induced P2Y6 receptor activation and enhanced P2Y1 receptor activation in cellular assays, revealing previously unreported purinergic-receptor activity for this molecule.
Technology: Consensus of deep learning, AdaBoost, naive Bayes, k-nearest neighbors, logistic regression, random forest, SVM and XGBoost classifiers
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Researchers used consensus machine-learning classifiers trained on known P2Y6 agonists to select compounds for pharmacological testing.
- Still unknown: The paper found no novel P2Y6 agonists, which was the initial aim. ABBV-744 inhibited P2Y6 activation at relatively high micromolar concentration (reported IC50 about 75.7 µM); its precise inhibitory mechanism was not determined and requires further assays. P2Y1 enhancement and weak P2Y14 binding effects are assay-specific observations, not clinical pharmacology or therapeutic benefit.
- AI role: Models trained on curated P2Y6 agonist activity data prioritized molecules from compound libraries for experimental screening. Functional calcium-transient assays in receptor-expressing cells and fluorescent binding assays were used to test predictions; ABBV-744 was the principal confirmed hit with unanticipated activity across P2Y receptor subtypes.
Evidence sources: https://link.springer.com/article/10.1007/s11302-024-10003-4
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 88 of works of the same type, year and subfield (OpenAlex work metrics, 10 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.